CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,332 enrolled
Drug / intervention
Boostrix® +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00835237
NCT00835237Phase 3Completed
CompareCT.gov

Evaluation of GSK Biologicals' Boostrix® Vaccine When Compared With Decavac™ in Adults Aged 65 Years or Older.

GlaxoSmithKline·interventional·Posted Feb 3, 2009·Updated Jan 3, 2020

In Brief

A Phase 3 clinical trial evaluating Boostrix® and Decavac™ for Tetanus and 3 related conditions. Completed, enrolled 1,332 participants across 24 sites.

Detailed Summary

This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2009
Enrollment StartFeb 17, 2009
Primary CompletionJul 23, 2009
Study CompletionOct 15, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.4 years ago

Interventions

Boostrix®biological

Intramuscular, single dose.

Decavac™biological

Intramuscular, single dose.